BioSpace

Structural gaps in areas including clinical execution and funding limit India’s ability to scale up innovation, according to a report from @BCG and HealthKois. #lifesciences #india #biospace hubs.li/Q04pRM8Z0

BioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026. hubs.li/Q04pRNh90

Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said. hubs.li/Q04pRM460

Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up. hubs.li/Q04pRN8t0

Journal publications that suggested changes in FDA guidelines do not “communicate FDA policy or interpretation of a regulatory issue,” acting director Kyle Diamantas wrote in a letter to House Energy & Commerce committee ranking member Diana DeGette. hubs.li/Q04pShph0

The FDAs enforcement action against Purolea Cosmetics Lab offers an early look at how the agency expects AI-generated work to fit within existing quality systems, with experts saying human oversight and quality controls remain essential. hubs.ly/Q04pNjDp0

With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry. hubs.li/Q04pLZTL0

Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options. hubs.li/Q04pL-2H0

Hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today. hubs.li/Q04pLGnw0

Takeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include @BioNTech_Group letting go of around 800 people at CureVac. #layoffs #biopharma #biospace hubs.li/Q04pL-3v0

Braveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is looking to establish its name in the cardiometabolic space. hubs.li/Q04pLmsg0

Psychedelics, chiefly Compass Pathways’ COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace. hubs.li/Q04pLH240

After committing $55 billion last year to bolster U.S. manufacturing capabilities, Johnson & Johnson is making changes to its pharmaceutical supply chain. hubs.li/Q04pGGlR0

The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Partners. hubs.li/Q04pBXPv0

Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist. hubs.li/Q04pBMBk0

New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau candidates from Denali Therapeutics, Eisai and Eli Lilly. hubs.li/Q04pBLJ60

Executive coach Angela Justice examines why the projects, questions, relationships and conversations people almost dismiss can become the ones they later recognize as turning points. #careerdevelopment #biopharma #biospace hubs.li/Q04pCRWC0

AI tools can help job seekers write resumes and mass apply to open positions, but those aren’t the only, or best, ways to use them. A career coach shares how she advises clients to use them during the job search process. #AI #biopharma #biospace hubs.li/Q04pC0cp0

Biogen’s new data supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup. hubs.li/Q04pC41N0

FDA rejected the combination therapy over manufacturing issues pertaining to Elevar’s rivoceranib. The rebuff is the third strike for the partners after the agency issued manufacturing-related denials for the other drug in the combo. hubs.li/Q04pBGJ-0